Deutsche Biotech Innovativ AG (DBI.DU)

1.3500 0.0000 (0.00%) As of 08:16AM CEST. Market open.

Deutsche Biotech Innovativ AG

Neuendorfstrasse 15a
Hennigsdorf 16761
Germany
49 3302 20 77 824
https://www.dbi-ag.de

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Bernd Wegener FRICS	Chairman of Management Board & Chief Executive Officer	N/A	N/A	1947
Dr. Metod Miklus	COO & Member of Management Board	N/A	N/A	1959
Dr. Frauke Hein Ph.D.	Chief Business Officer & Head of Business Development	N/A	N/A	N/A
Dr. Joachim Struck	Head of Research & Development	N/A	N/A	N/A
Dr. Jens Zimmermann	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Deutsche Biotech Innovativ AG operates as a biotechnology company in Germany. The company develops Adrecizumab, an antibody-based therapy that has completed the Phase I/II clinical trial for the treatment of septic shock. It also focuses on the development of various drugs for the treatment of solid tumor, organ failure, rosacea, neurodermatitis, pharyngitis, and Alzheimer's diseases. The company was formerly known as Venetus Beteiligungen AG and changed its name to Deutsche Biotech Innovativ AG in August 2014. Deutsche Biotech Innovativ AG was founded in 2009 and is based in Hennigsdorf, Germany.

Corporate governance

Deutsche Biotech Innovativ AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.